Table 3.
Effects of compounds 4b, 4e–g, 4i–j and 4l–m on K562 cell cycle progression
| Compound | IC50a (nM) | IC100b (nM) | Cell cycle distribution (%) | |||
|---|---|---|---|---|---|---|
| Sub-G1c | G0G1 | S | G2/M | |||
| Control | 3.76 | 34.6 | 50.4 | 15.1 | ||
| 4b | 220 ± 50 | 800 | 8.28 | 2.13 | 18.9 | 78.9 |
| 4e | 95 ± 2 | 150 | 17.7 | 14.8 | 26.8 | 58.3 |
| 4f | 180 ± 20 | 500 | 6.00 | 3.72 | 13.8 | 82.5 |
| 4g | 38 ± 7 | 85 | 7.92 | 3.74 | 16.9 | 79.4 |
| 4i | 6 ± 0.1 | 25 | 7.80 | 11.7 | 22.1 | 66.2 |
| 4j | 42 ± 5 | 75 | 9.46 | 4.19 | 15.2 | 80.6 |
| 4l | 47 ± 8 | 230 | 11.2 | 10.8 | 38.1 | 51.2 |
| 4m | 220 ± 40 | 400 | 10.5 | 6.16 | 17.1 | 76.7 |
a
Compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SE from the dose–response curves of at least three independent experiments.
b
Compound concentration required to inhibit tumor cell proliferation by 100%.
c
Percentage of the cell population with hypodiploid DNA content peak (apoptotic cells).